For a major pharmaceutical company, Brattle provided expert testimony before an arbitration panel on the damages that the company suffered due to the termination of a co-marketing agreement for a prescription hormone replacement therapy. The client’s co-marketing partner terminated the agreement just as the product reached a breakeven point, and well before the agreement was due to expire. Our expert quantified the profits that the pharmaceutical company would have earned if the agreement had run its expected course, as well as the profits the company could have expected to earn on its existing portfolio of products if it had never entered into the agreement. In response to Brattle’s testimony, the arbitration panel awarded the pharmaceutical company approximately $60 million in damages.